Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation

Ankit J Kansagra; Noelle V Frey; Merav Bar; Theodore W Laetsch; Paul A Carpenter; Bipin N Savani; Helen E Heslop; Catherine M Bollard; Krishna V Komanduri; Dennis A Gastineau; Christian Chabannon; Miguel A Perales; Michael Hudecek; Mahmoud Aljurf; Leslie Andritsos; John A Barrett; Veronika Bachanova; Chiara Bonini; Armin Ghobadi; Saar I Gill; Joshua Hill; Saad Kenderian; Partow Kebriaei; Arnon Nagler; David Maloney; Hien D Liu; Nirali N Shah; Mohamed A Kharfan-Dabaja; Elizabeth J Shpall; Ghulam J Mufti; Laura Johnston; Elad Jacoby; Ali Bazarbachi; John F DiPersio; Steven Z Pavletic; David L Porter; Stephan A Grupp; Michel Sadelain; Mark R Litzow; Mohamad Mohty; Shahrukh K Hashmi

doi:10.1016/j.bbmt.2018.12.068

Back

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation

Journal article

Peer reviewed

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation

Ankit J Kansagra, Noelle V Frey, Merav Bar, Theodore W Laetsch, Paul A Carpenter, Bipin N Savani, Helen E Heslop, Catherine M Bollard, Krishna V Komanduri, Dennis A Gastineau, …

Biology of blood and marrow transplantation, Vol.25(3), pp.e76-e85

2019-03

DOI: https://doi.org/10.1016/j.bbmt.2018.12.068

PMID: 30576834

Abstract

Immunotherapy, Adoptive - methods

United States

Humans

Receptors, Antigen, T-Cell - therapeutic use

Drug Approval

Practice Patterns, Physicians

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy

Critical Pathways

Young Adult

Societies, Medical

Child

Expert Testimony

Antigens, CD19 - immunology

On August 30, 2017 the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present, ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring, and disease assessments. To address these issues experts representing the American Society for Blood and Marrow Transplant, the European Society for Blood and Marrow Transplantation, the International Society of Cell and Gene Therapy, and the Foundation for the Accreditation of Cellular Therapy formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Metrics

16 Record Views

See more details

Details

Title: Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation
Creators: Ankit J Kansagra - Department of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
Noelle V Frey - Cell Therapy and Transplant Program, Abramson Cancer Center and the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
Merav Bar - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington
Theodore W Laetsch - Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Health, Dallas, Texas
Paul A Carpenter - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington
Bipin N Savani - Division of Hematology/Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
Helen E Heslop - Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, Texas
Catherine M Bollard - Center for Cancer and Immunology Research, Children's National Health System, Washington, DC
Krishna V Komanduri - Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida
Dennis A Gastineau - Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, Arizona
Christian Chabannon - Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer; Centre d'Investigations Cliniques en Biothérapie, Université d'Aix-Marseille, Inserm CBT 1409, Marseille, France
Miguel A Perales - Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York
Michael Hudecek - Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
Mahmoud Aljurf - Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Leslie Andritsos - Division of Hematology, Ohio State University Wexner Medical Center, Columbus, Ohio
John A Barrett - Stem Cell Transplantation and Cellular Therapy Program, GW Cancer Center, George Washington University, Washington, DC
Veronika Bachanova - Division of Hematology/Oncology/Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota
Chiara Bonini - Experimental Hematology Unit, University Vita-Salute San Raffaele and Ospedale San Raffaele, Milano, Italy
Armin Ghobadi - Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
Saar I Gill - Cell Therapy and Transplant Program, Abramson Cancer Center and the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
Joshua Hill - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington
Saad Kenderian - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota; Department of Immunology, Mayo Clinic, Rochester, Minnesota
Partow Kebriaei - Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
Arnon Nagler - The Chaim Sheba Medical Center, Tel-Hashomer, Affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
David Maloney - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington
Hien D Liu - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Nirali N Shah - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Mohamed A Kharfan-Dabaja - Division of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida
Elizabeth J Shpall - Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
Ghulam J Mufti - Department of Haematological Medicine, King's College, London, United Kingdom
Laura Johnston - Department of Medicine, Stanford University School of Medicine, Stanford, California
Elad Jacoby - The Chaim Sheba Medical Center, Tel-Hashomer, Affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Ali Bazarbachi - Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
John F DiPersio - Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
Steven Z Pavletic - Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
David L Porter - Cell Therapy and Transplant Program, Abramson Cancer Center and the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
Stephan A Grupp - Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania
Michel Sadelain - Center for Cell Engineering and Immunology Program, Sloan Kettering Institute, New York, New York
Mark R Litzow - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota
Mohamad Mohty - Hôpital Saint-Antoine, APHP, Sorbonne Universite, INSERM UMRs 938, Paris, France
Shahrukh K Hashmi - Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: sharukh3@yahoo.com
Publication Details: Biology of blood and marrow transplantation, Vol.25(3), pp.e76-e85
Publisher: United States
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 30576834
Record Identifier: 991031561605102976